Asperlicin

Asperlicin
	(S-(2α,9β,9(R*),9α,β))-6,7-Dihydro-7-((2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo(1,2-a)indol-9-yl)methyl)quinazolino(3,2-a)(1,4)benzodiazepine-5,13-dione
Identifikacija
CAS registarski broj	93413-04-8
PubChem	3035433
Jmol-3D slike	Slika 1
SMILES
	CC(C)C[C@H]1C(=O)N2[C@H](N1)[C@@](C3=CC=CC=C32)(C[C@H]4C5=NC6=CC=CC=C6C(=O)N5C7=CC=CC=C7C(=O)N4)O
InChI
	InChI=1S/C31H29N5O4/c1-17(2)15-22-29(39)36-25-14-8-5-11-20(25)31(40,30(36)34-22)16-23-26-32-21-12-6-3-9-18(21)28(38)35(26)24-13-7-4-10-19(24)27(37)33-23/h3-14,17,22-23,30,34,40H,15-16H2,1-2H3,(H,33,37)/t22-,23-,30-,31-/m0/s1 ; Kod: MGMRIOLWEROPJY-FPACPZPDSA-N
Svojstva
Molekulska formula	C31H29N5O4
Molarna masa	535.593
	(šta je ovo?) (verifikuj) ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

Asperlicin je mikotoksin, izveden ih funguss Aspergillus alliaceus. On deluje kao selektivni antagonist holecistokininskog receptora CCK_A.^[3]^[4]^[5] On je bio vodeće jedinjenje za razvoj brojnih novih CCK_A antagonista sa mogućim kliničkim primenama.^[6]^[7]^[8]^[9]

Literatura[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Chang RS, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schönberg G, Patchett AA, Liesch JM, Hensens OD, et al. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science. 1985 Oct 11;230(4722):177-9. PMID 2994227
↑ Goetz MA, Lopez M, Monaghan RL, Chang RS, Lotti VJ, Chen TB. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties. Journal of Antibiotics (Tokyo). 1985 Dec;38(12):1633-7. PMID 3005212
↑ Liesch JM, Hensens OD, Springer JP, Chang RS, Lotti VJ. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Structure elucidation. Journal of Antibiotics (Tokyo). 1985 Dec;38(12):1638-41. PMID 3841533
↑ Bock MG, DiPardo RM, Rittle KE, Evans BE, Freidinger RM, Veber DF, Chang RS, Chen TB, Keegan ME, Lotti VJ. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility. Journal of Medicinal Chemistry. 1986 Oct;29(10):1941-5. PMID 3761313
↑ Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Gould NP, Lundell GF, Homnick CF, Veber DF, et al. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists. Journal of Medicinal Chemistry. 1987 Jul;30(7):1229-39. PMID 2885419
↑ Van der Bent A, Ter Laak AM, IJzerman AP, Soudijn W. Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists. European Journal of Pharmacology. 1992 Aug 3;226(4):327-34. PMID 1397061
↑ Lattmann E, Billington DC, Poyner DR, Howitt SB, Offel M. Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists. Drug Design and Discovery. 2001;17(3):219-30. PMID 11469752

Spoljašnje veze[uredi | uredi kod]

Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Chang RS, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schönberg G, Patchett AA, Liesch JM, Hensens OD, et al. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science. 1985 Oct 11;230(4722):177-9. PMID 2994227

[4] Goetz MA, Lopez M, Monaghan RL, Chang RS, Lotti VJ, Chen TB. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties. Journal of Antibiotics (Tokyo). 1985 Dec;38(12):1633-7. PMID 3005212

[5] Liesch JM, Hensens OD, Springer JP, Chang RS, Lotti VJ. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Structure elucidation. Journal of Antibiotics (Tokyo). 1985 Dec;38(12):1638-41. PMID 3841533

[6] Bock MG, DiPardo RM, Rittle KE, Evans BE, Freidinger RM, Veber DF, Chang RS, Chen TB, Keegan ME, Lotti VJ. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility. Journal of Medicinal Chemistry. 1986 Oct;29(10):1941-5. PMID 3761313

[7] Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Gould NP, Lundell GF, Homnick CF, Veber DF, et al. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists. Journal of Medicinal Chemistry. 1987 Jul;30(7):1229-39. PMID 2885419

[8] Van der Bent A, Ter Laak AM, IJzerman AP, Soudijn W. Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists. European Journal of Pharmacology. 1992 Aug 3;226(4):327-34. PMID 1397061

[9] Lattmann E, Billington DC, Poyner DR, Howitt SB, Offel M. Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists. Drug Design and Discovery. 2001;17(3):219-30. PMID 11469752

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

Asperlicin

Literatura[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga